KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to -$18.8 million.

  • Halozyme Therapeutics' Change in Inventory fell 34308.83% to -$18.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.6 million, marking a year-over-year decrease of 10379.04%. This contributed to the annual value of -$2.6 million for FY2025, which is 10379.04% down from last year.
  • Halozyme Therapeutics' Change in Inventory amounted to -$18.8 million in Q4 2025, which was down 34308.83% from $1.1 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Change in Inventory high stood at $40.2 million for Q1 2024, and its period low was -$18.8 million during Q4 2025.
  • Its 5-year average for Change in Inventory is $5.1 million, with a median of $843500.0 in 2025.
  • As far as peak fluctuations go, Halozyme Therapeutics' Change in Inventory surged by 1771744.19% in 2022, and later plummeted by 34308.83% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Change in Inventory stood at -$2.2 million in 2021, then surged by 232.72% to $2.9 million in 2022, then plummeted by 149.88% to -$1.5 million in 2023, then surged by 625.94% to $7.7 million in 2024, then plummeted by 343.09% to -$18.8 million in 2025.
  • Its Change in Inventory stands at -$18.8 million for Q4 2025, versus $1.1 million for Q3 2025 and $14.5 million for Q2 2025.